Tenofovir Alafenamide Powder CAS 379270-37-8

AIDS is a disease that causes many people around the world to lose their lives. Although the treatment plan for this disease is making continuous progress, there is still a lack of a comprehensive and effective treatment approach. It was not until recently that people began to use a new type of drug, Tenofovir Alafenamide, to treat AIDS and viral hepatitis. For this new type of drug, people advocate it even more as an efficient treatment method.

Tenofovir Alafenamide Powder is a novel nucleotide reverse transcriptase inhibitor. Once inside liver cells, the drug hydrolyzes into tenofovir. Tenofovir is then phosphorylated by intracellular kinases to become pharmacologically active Tenofovir diphosphate. Tenofovir bisphosphonates are integrated into viral DNA by HBV reverse transcriptase, resulting in disruption of DNA strand synthesis.
Tenofovir alafenamide is an antiretroviral drug used clinically in its fumarate form to treat hepatitis B or in combination with other drugs to treat HIV.

Tenofovir Alafenamide Powder may cause adverse reactions such as headache, vomiting, diarrhea, fatigue, gastric discomfort, increased liver enzymes and increased blood glucose. In addition, this drug has been proven to cause kidney problems, including acute renal failure, kidney stones and tubular damage. Therefore, patients who have been using this drug for a long time should have regular renal function tests.

Compared with Tenofovir dipivoxil, the plasma concentration of Tenofovir Alafenamide was 91% lower, while the intracellular concentration was approximately 20 times higher. This is due to its long-term systemic exposure and the high accumulation of its active metabolite tenofovir diphosphate within cells. Compared with red blood cells, Tenofovir Alafenamide accumulates more in peripheral blood mononuclear cells. Once activated, tenofovir works through various mechanisms, including inhibiting viral polymerase, causing chain termination and suppressing viral synthesis. Entecavir and tenofovir are both recognized as drugs with excellent antiviral effects for treating hepatitis B. However, compared with entecavir, tenofovir can be used for the treatment of pregnant women and patients in the preconception period, and it has better safety.